First Horizon Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History

First Horizon Advisors, Inc.

$3.58 Billion
Q3 2024

A detailed history of First Horizon Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 2,163 shares of VRTX stock, worth $975,448. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,163

Previous 2,190 1.23%

Holding current value

$975,448

Previous $1.03 Million 2.05%

% of portfolio

0.03%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$460.0 - $505.78 $12,420 - $13,656	-27 Reduced 1.23%	2,163 $1.01 Million
Q2 2024 Jul 19, 2024	SELL	$392.81 - $485.53 $9,427 - $11,652	-24 Reduced 1.08%	2,190 $1.03 Million
Q1 2024 Apr 26, 2024	BUY	$407.69 - $446.08 $520,620 - $569,644	1,277 Added 136.29%	2,214 $925,000
Q4 2023 Feb 06, 2024	BUY	$343.0 - $410.68 $26,754 - $32,033	78 Added 9.08%	937 $381,000
Q3 2023 Oct 27, 2023	BUY	$338.18 - $362.46 $183,631 - $196,815	543 Added 171.84%	859 $298,000
Q2 2023 Aug 03, 2023	SELL	$314.42 - $351.91 $5,345 - $5,982	-17 Reduced 5.11%	316 $111,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $1,132 - $1,292	4 Added 1.22%	333 $104,000
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $6,858 - $7,715	24 Added 7.87%	329 $95,000
Q3 2022 Nov 09, 2022	BUY	$273.83 - $305.53 $4,107 - $4,582	15 Added 5.17%	305 $88,000
Q2 2022 Aug 02, 2022	BUY	$234.96 - $292.55 $39,943 - $49,733	170 Added 141.67%	290 $81,000
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $8,635 - $10,177	-39 Reduced 24.53%	120 $31,000
Q4 2021 Feb 09, 2022	SELL	$177.01 - $223.45 $15,576 - $19,663	-88 Reduced 35.63%	159 $34,000
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $31,743 - $35,523	-175 Reduced 41.47%	247 $44,000
Q3 2021 Nov 09, 2021	BUY	$181.39 - $202.99 $32,287 - $36,132	178 Added 72.95%	422 $76,000
Q2 2021 Aug 09, 2021	SELL	$187.49 - $221.1 $35,435 - $41,787	-189 Reduced 43.65%	244 $49,000
Q1 2021 May 11, 2021	BUY	$207.02 - $241.31 $39,126 - $45,607	189 Added 77.46%	433 $93,000
Q3 2020 Nov 12, 2020	SELL	$255.65 - $303.1 $6,391 - $7,577	-25 Reduced 9.29%	244 $66,000
Q1 2020 May 05, 2020	BUY	$199.77 - $247.81 $6,792 - $8,425	34 Added 14.47%	269 $64,000
Q4 2019 Jan 07, 2020	BUY	$166.71 - $223.91 $15,837 - $21,271	95 Added 67.86%	235 $51,000
Q3 2019 Oct 23, 2019	SELL	$166.23 - $187.09 $8,643 - $9,728	-52 Reduced 27.08%	140 $23,000
Q2 2019 Aug 05, 2019	BUY	$164.61 - $190.37 $493 - $571	3 Added 1.59%	192 $0
Q1 2019 Apr 26, 2019	BUY	$163.73 - $194.7 $29,143 - $34,656	178 Added 1618.18%	189 $0
Q4 2018 Feb 11, 2019	SELL	$151.91 - $192.21 $303 - $384	-2 Reduced 15.38%	11 $1,000
Q3 2018 Nov 05, 2018	SELL	$167.73 - $192.74 $19,959 - $22,936	-119 Reduced 90.15%	13 $0
Q4 2017 Jan 25, 2018	SELL	$137.28 - $155.55 $18,120 - $20,532	-132 Reduced 50.0%	132 $0
Q3 2017 Nov 09, 2017	SELL	$148.13 - $162.24 $1,481 - $1,622	-10 Reduced 3.65%	264 $0
Q2 2017 Aug 14, 2017	BUY	N/A	274	274 $0

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.

Account

First Horizon Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History